{name}
{subtitle}
Efficacy, Safety, and Tolerability of V937 Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)
city
~11 mi. (La Tronche, France, +25 more cities)
facility
CHU de Grenoble Hopital Nord ( Site 2027)
drug
coxsackievirus A21, +1 more drug
FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation
city
~54 mi. (Sainte-Colombe, France, +41 more cities)
facility
Clinique Trenel
drug
fluorouracil, +3 more drugs
drug type
chemotherapy, +2 more types
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
city
~58 mi. (Valence, France, +137 more cities)
facility
Centre Hospitalier de Valence-Service de Dermatologie ( Site 0377)
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors
city
~64 mi. (Lyon 08, France, +29 more cities)
facility
Centre Leon Berard /ID# 218515
biomarker
ER Negative, +2 more biomarkers
condition
Breast Adenocarcinoma, +1 more condition
drug
ABBV-151, +1 more drug
drug type
immunotherapy, +1 more type
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
city
~64 mi. (Lyon 08, France, +29 more cities)
facility
Centre Leon Berard /ID# 163707
drug
chemotherapy, +1 more drug
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
city
~64 mi. (Lyon 08, France, +24 more cities)
facility
Centre Leon Berard /ID# 217910
biomarker
ER Negative, +2 more biomarkers
condition
Breast Adenocarcinoma, +2 more conditions
drug
ABBV-368, +5 more drugs
drug type
chemotherapy, +1 more type